

CURRICULUM VITAE

MÁRCIO AUGUSTO DINIZ

Marcio.diniz@mountsinai.org

December 08, 2023

APPOINTMENTS/EMPLOYMENT

May/2012 – Feb/2015	Biostatistician, School of Medicine, University of São Paulo, São Paulo, Brazil
Nov/2015 – Dec/2020	Research Scientist I, Biostatistics and Bioinformatics Research Center, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, US
Jan/2018 – Dec/2022	Assistant Professor, Department of Medicine, Cedars-Sinai Medical Center, US
Jan/2020 – April/2023	Research Scientist II, Biostatistics and Bioinformatics Research Center, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, US
Jan/2023 – April/2023	Associate Professor, Department of Medicine, Cedars-Sinai Medical Center, US
May/2023 - Present	Associate Professor, Department of Population Health Science and Policy, Icahn School of Medicine, US - Pending

GAPS IN EMPLOYMENT

Not applicable.

EDUCATION

2005 – 2008	B.S., Statistics, University of Campinas, Campinas, Brazil
2009 – 2011	M.S., Statistics, University of Campinas, Campinas, Brazil
2011 – 2015	Ph.D., Statistics, University of São Paulo, São Paulo, Brazil

CERTIFICATION

Not applicable.

LICENSURE

Not applicable.

HONORS/AWARDS

2020	David L. Rimoin Teaching Excellence Award, Cedars-Sinai Medical Center
2021	David L. Rimoin Teaching Excellence Award, Cedars-Sinai Medical Center

PATENTS

Not applicable.

OTHER ENTREPRENEURIAL ACTIVITIES

Not applicable.

OTHER PROFESSIONAL ROLES

Intramural committees

Feb/2017 – Dec/2018	Safety Committee on Early Phase Studies, Cedars-Sinai Medical Center, US
Jan/2019 – April/2022	Data & Safety Monitoring Committee, Cedars-Sinai Medical Center, US
Jan/2019 – April/2023	Biomedical Sciences PhD Curriculum Committee, Cedars-Sinai Medical Center, US
Jan/2020 – Oct/2020	Faculty Search Committee – Faculty Biostatistician, Cedars-Sinai Medical Center, US
Jan/2022 – May/2023	Faculty Search Committee – Faculty Biostatistician, Cedars-Sinai Medical Center, US
May/2022 – April/2023	Protocol Review and Monitoring Committee, Cedars-Sinai Medical Center, US
Jan/2022 – May/2023	Faculty Search Committee – Faculty Biostatistician, Cedars-Sinai Medical Center, US
May/2023 – Present	Investigator Initiated Trials Review Committee, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, US

Extramural committees

2021 - 2021	Scleroderma Idea Development Program – Department of Defense
2021 - Present	Data & Safety Monitoring Board for In-Home Obesity Prevention To Reach Low-Income Infants Through Maternal And Social Transmission - NCT03529695 - NICHD; R01HD092483-A1
2022 - 2022	DOD USAMRDC Broad Agency Announcement for Extramural Medical Research – Department of Defense
2023 - Present	Data & Safety Monitoring Board for In-Home Obesity Prevention To A PiLot CLinical TrIal of PARicalcitol for ChroNic PanCrEatitIs (Alliance) - NCT05664880 – NIH; R01DK132631

PhD/Master's program Committee

2020 – 2021	Jadson Luan dos Santos Marcelino - Master Thesis Committee, Institute of Mathematics and Computer Sciences, Federal University of São Carlos, Brazil
2021 – 2022	Amber DeVries - PhD Dissertation Committee, Graduate School of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, United States
2021 – 2022	Peter Nguyen - PhD Dissertation Committee, Graduate School of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, United States
2023 – Present	Nicholas Venturini – MD/PhD Dissertation Committee, Graduate School of Biomedical Sciences, Icahn School of Medicine, New York City, United States
2023 – Present	John Durbin - MD/PhD Dissertation Committee, Graduate School of Biomedical Sciences, Icahn School of Medicine, New York City, United States

Scientific Societies

2014 –	Brazilian Statistical Association
2015 –	American Statistical Association

RESEARCH PROFILE

As a biostatistician for the last 10 years, I have dedicated myself to the design and analysis of clinical data using a spectrum of study designs, from pilot studies to community intervention trials, in a variety of clinical areas, including cancer, cardiology, psychiatry, gerontology, health services and gastroenterology. I have extensive experience providing statistical support to clinical investigators using conventional

statistical techniques such as linear mixed models and survival models and novel methods such as propensity score analysis and regularized regression models. Throughout I have continuously promoted the adoption of good practices to ensure statistical rigor and reproducible research.

My primary area of research interest focuses on novel adaptive clinical trial designs. I have proposed Bayesian phase I designs for cancer trials aiming to identify the maximum tolerable dose of single cytotoxic agent or combination of cytotoxic agents while considering strategies to make efficient use of limited information. The latter is particularly important in phase I trials, a first step of translation of new drugs from laboratory research to clinical practice, which are typically limited in their sample sizes. More recently, I have focused on efficient designs for phase II trials, which play a pivotal role as gatekeepers for conducting larger studies. More specifically, I extended the dose-ranging trial design MCP-Mod (a design considered to be "fit-for-purpose" by the FDA) to accommodate small sample sizes with time-to-event endpoints such as progression free-survival, adopted for use for trials of immunotherapies in human and overall survival studies in animal. This methodological advance can reduce the percentage of false-positive phase II trials, thereby avoiding unnecessary use of resources on testing non-promising interventions. My future work will continue to focus on development of efficient clinical trial designs that are motivated by my collaborations with clinical investigators at the Tisch Cancer Institute.

CLINICAL PROFILE

Not applicable.

OVERALL IMPACT

My primary role as a member of the Biostatistics and Clinical Informatics Core is collaborative, providing statistical support to clinical investigators when designing clinical and pre-clinical studies. Based on my strong theoretical foundation in statistics, I am able to apply state-of-art statistical methods to medical research questions, and have successfully garnered federal funding for this work through the grant process. More recently, my work led to FDA approval of a biomarker for impending preterm preeclampsia that looks at the ratio between the levels of two proteins that are involved in blood vessel development in the placenta. Furthermore, I have been the senior statistician for Pre-Clinical Network (SPAN) since its inception, a multi-laboratory preclinical assessment network, funded by the National Institute of Neurological Disorders and Stroke, which implements state-of-the-art experimental designs to test the hypothesis that rigorous preclinical assessment can successfully reduce or eliminate common sources of bias in choosing treatments for human studies.

DIVERSITY AND INCLUSION IMPACT

My work as a statistician includes productive collaborations with investigators focusing on health disparities and women's health. My statistical contributions to these collaborative efforts have resulted in significant external funding. In particular, I have disseminated statistical methods to incorporate sex as biological variable and discussed the lack of representation of women in coronary artery disease trials. As an immigrant Latino and first-generation, I am deeply aware of the struggles that minorities deal with as PhD students throughout their path to become successful junior investigators. Therefore, prioritizing investigators from minorities groups or with research on minorities has been a goal in my career as a biostatistician. Furthermore, I have volunteered to be a speaker about career as a biostatistician in Skype a Scientist (<https://www.skypeascientist.com/>) for students in US and contributed with multimedia educational material to public school students in Brazil.

MENTORING PROFILE

As a collaborative statistician, I acknowledge that investigators might not have strong statistical background whether they are students or senior investigators. As science has become more collaborative over the decades, the interaction between statisticians and investigators with different expertise subjects is a unique opportunity to an enriching exchange of knowledge. My ability to translate complex statistical concepts to non-statisticians has made those interactions with researchers of different levels to be very successful as can be attested by my extensive list of early-career grants contributing as a co-investigator. Furthermore, I have mentored master level and Ph.D. level statisticians at the Biostatistics Core introducing innovative methodologies, standardized reporting methods for statistical analyses and grant writing. Finally, I also have developed teaching material about basic statistical methods and common tools used in basic science and clinical research that is disseminated in stand-alone lectures and courses.

GRANTS, CONTRACTS, FOUNDATION SUPPORT

PAST GRANTS

List Funding Source	Role in Project	Dates	Direct Costs	Supplemental Info
W81XWH-12-1-0447	Biostatistician, 6.0 CM	Nov/2015 – Sep/2017	NA	Detecting and Elimination of Oncogenic Signaling Networks in Pre-Malignant & Malignant Cells with Magnetic-Resonance Imaging (Herbert Lyerly)
UL1 TR001881	Co-Investigator, 0.3 CM	Jul/2016 – Apr/2023	\$12,719,699	UCLA Clinical and Translational Science Institute (Steven Dubinett)
P01 CA098912-11	Biostatistician, 0.96 CM	Mar/2017 – Feb/2020	\$24,036,828	Prostate Cancer Bone Metastasis: Biology and Targeting – Biostatistics Core (Leland Chung)
SMPAI-2017C2-7716	Co-Investigator, 1.44 CM	Jul/2018 – Oct/2022	\$2,633,608	Personalized Treatments for Depressive Symptoms in Advanced Heart Failure (Ishak Waguhi)
U01 CA232859	Co-Investigator, 1.2 CM	Sep/2018 – Apr/2023	\$2,725,138	Advancing Analysis and Interpretation of Adverse Events and PROs in Cancer Clinical Trials (Andre Rogatko and Patricia Gantz)
Cedars Sinai Precision Medicine	Biostatistician, 0.6 CM	Feb/2019 – Jan/2020	\$100,000	A Retrospective Pilot Study of the Utility of Circulating Biomarker Panels to Improve Selection of Candidates for Non-Invasive Coronary Artery Calcium Imaging (Sarah Parker)
R01 HL147355	Co-Investigator, 1.2 CM	Apr/2019 – Oct/2020	\$1,762,727	Longitudinal and quantitative MR plaque imaging for prediction of response to medical management in symptomatic intracranial atherosclerosis (Zhaoyang Fan)
U24 NS113452	Biostatistician, 1.2 CM	Aug/2019 – Jul/2022	\$2,374,538	The NIH SPAN Coordinating Center (Patrick Lyden)
W81XWH-18-PCRP-HDRA	Co-Investigator, 0.24 CM	Sep/2019 – Aug/2021	NA	Do Black Men with Metastatic Castration-Resistant Prostate Cancer Have Worse Outcomes than White Patients? A Nationwide VA Study (Adriana Vidal)
R34 DA050255	Co-Investigator, 0.36 CM	Sep/2019 – Mar/2021	NA	Planning Phase for the Healthy Brain and child Development Study In Los Angeles County Area (Wei Gao)
W81XWH1910888	Co-Investigator, 0.6 CM	Sep/2019 – Apr/2023	\$1,990,288	Mechanisms and Treatment Development for Pancreatitis Resulting from Alcohol Abuse and Smoking (Stephen Pandol)
ThermoFisher Scientific	Biostatistician, 0.12 CM	Nov/2019 – Aug/2022	NA	Identification and Validation of a Cut-off for the Ratio of Soluble Fms-like Tyrosine Kinase-1 to Placental Growth Factor (sFlt-1/PIGF) to Stratify Risk in Pregnant Women with Hypertensive Disorders of Pregnancy (Ananth Karumanchi)
ZZ-3K3A-301	Biostatistician, 0.6 CM	Apr/2020 – Feb/2022	NA	A multicenter, randomized, placebo-controlled, double-blinded, Phase 3 study to evaluate the efficacy and safety of 3K3A-APC (Patrick Lyden)

R01 HL148787-01A1	Co-Investigator, 0.6 CM	May/2020 – Apr/2023	\$1,984,308	Integrated Prediction of Cardiovascular events by automated coronary plaque and pericoronary adipose tissue quantification from CT Angiography (Damini Dey)
R01 HL089765	Co-Investigator, 0.6 CM	Jun/2020 – May/2022	\$6,124,030	Quantitative Prediction of Disease and Outcomes from Next Generation SPECT and CT (Piotr Slomka)
U54 AG065141	Co-Investigator, 0.6 CM	Jul/2020 – Apr/2023	\$3,438,143	The Microvascular Aging and Eicosanoids – Women’s Evaluation of Systemic Aging Tenacity (MAE-WEST) ("You are never too old to become younger!") Specialized Center for Research Excellence (Noel Bairey-Merz and Susan Cheng)
Pancreatic Cancer Action Network	Biostatistician, 0.6 CM	Jul/2020 – Jun/2022	\$180,909	Evaluating Objective Measures of Physical Function in Pancreatic Cancer (Gillian Gresham)
American College of Gastroenterology	Biostatistician, 0.24 CM	Jul/2020 – Jun/2023	\$300,000	EVS as Novel Circulating Biomarker for HCC (Ju Dong Yang)
Cedars Sinai – Internal Grant	Biostatistician, 0.12 CM	Sep/2020 – Sep/2021	\$100,000	Predicting Pancreatic Ductal Adenocarcinoma (PDAC) using artificial Intelligence Analysis of Computed Tomography and Non-Imaging Indicators (Debiao Li)
ThermoFisher	Biostatistician, 0.6 CM	Jan/2021 – Dec/2023	\$303,846	First Trimester Risk Assessment for Preeclampsia (Ananth Karumanchi)
R01 CA260955-01	Co-Investigator, 0.6 CM	Apr/2021 – Mar/2026	\$1,160,586	Predicting Pancreatic Ductal Adenocarcinoma (PDAC) Through Artificial Intelligence Analysis of Pre-Diagnostic CT Images (Debiao Li)
R01CA258222	Co-Investigator, 1.2 CM	Jun/2021 – May/2026	\$1,647,279	Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators (Jane Figueiredo, Courtney Peterson, and Sarah Salvy)
Pfizer	Biostatistician, 0.48 CM	Jun/2021 – Jun/2022	\$197,000	Optimize systemic platform to assure quality, value and evidence-based decision making on biosimilar products use in oncology patients (Suwicha Limvorasak)
R01CA252042	Co-Investigator, 0.12 CM	Jul/2021 – Apr/2026	\$1,356,585	Discovery and verification of methylated circulating tumor DNA markers for the detection of colorectal cancer in subjects under 50 years of age (Megan Hitchins, Robert Haile, and Sungyong You)
Cedars Sinai Center For Integrated Research In Cancer And Lifestyle	Biostatistician, 0.12 CM	Oct/2021 – Sep/2023	\$100,000	Walk and Play (Sarah Salvy)
Cedars Sinai Center For Integrated Research In Cancer And Lifestyle	Biostatistician, 0.12 CM	Oct/2021 – Sep/2023	\$10,000	Quantifying the 24-hour Movement Continuum in Cancer Survivors (Gillian Gresham and Celina Shirazipour)
HIS-2019C3-17863	Co-Investigator, 0.84 CM	Jan/2022 – Apr/2025	\$2,306,797	Elders Preserving Independence in the Community (Harriet Aronow)
R01DK130851	Co-Investigator, 1.2 CM	Feb/2022 – May/2027	NA	Evaluating environmental control (AVOID) and inhibitory control (RESIST) strategies to improve weight

				management outcomes (Sarah Salvy)
UG3NS119199-01A1	Biostatistician, 0.36 CM	May/2022 - Jan/2027	\$3,980,070	A multicenter, randomized, placebo controlled, double-blinded, Phase 3 study to evaluate the efficacy and safety of 3K3A-APC (Patrick Lyden)
1R35HL161195-01	Co-Investigator, 0.24 CM	Jun/2022 – May/2029	\$1,027,005	Patient-specific Outcome Prediction from Cardiovascular Multimodality Imaging by Artificial Intelligence (Piotr Slomka)
R01HL146158-04	Co-Investigator, 0.36 CM	Jul/2022 – Nov/2023	NA	Women's Ischemia Syndrome Evaluation (WISE) - Mechanisms of Coronary Microvascular Dysfunction Leading to Pre-Heart Failure with Preserved Ejection Fraction (Noel Bairey-Merz)
W81XWH-17-2-0030	Co-Investigator, 0.36 CM	Jul/2022 – Sep/2023	\$1,766,058	Ischemia Intensive Medical Treatment Reduces Events in Women with Non-Obstructive CAD (Noel Bairey-Merz)
W81XWH-22-1-0632	Co-Investigator, 0.45 CM	Jul/2022 - Jun/2027	NA	A Deep Learning Strategy to Integrate Karyometric Features with Underlying Molecular Pathways in Ovarian Cancer Initiation (Arkadius Gertych and Sanda Orsulic)
W81XWH-22-1-0736	Co-Investigator, 0.24 CM	Jul/2022- Jun/2025	NA	Risk Stratification of Pancreatic Ductal Adenocarcinoma in New-onset Diabetes Using Artificial Intelligence Analysis of Retinal Images (Touseef Qureshi and Debiao Li)
R01EB034586 - 01A1	Co-Investigator, 0.48 CM	Sep/2022 – Aug/2026	NA	Integrating Artificial Intelligence for Optimal Analysis of Cardiac PET/CT (Piotr Slomka)

CURRENT GRANTS

List Funding Source	Role in Project	Dates	Direct Costs	Supplemental Info
1U24NS130600-01	Co-Investigator, 2.4 CM	01/2023 – 12/2025	\$2,970,374	The NIH SPAN Coordinating Center (Patrick Lyden)
P30CA196521	Co-Investigator, 2.4 CM	5/2023 - 7/2025	\$14,497,296	The Tisch Cancer Institute - Cancer Center Support Grant (Ramon Parsons)

PENDING GRANTS

List Funding Source	Role in Project	Dates	Direct Costs	Supplemental Info

CLINICAL TRIALS PARTICIPATION

Project	Role in Project	Dates	Award	Other Info
Elders Preserving Independence in the Community (EPIC)	Study Design	Aug/22 – July/24	PCORI	NCT05381480
Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women	Study Design	Jul/22 – Jul/24	CA Breast Cancer Research Program	NCT05298605

Avoid and Resist Strategies for Weight Management	Study Design	Jun/22 – Feb/27	NIH	NCT05143931
Cognitive Training Through Gaming and Walking	Study Design	Jun/22 – May/23	Institutional Funds	NCT04638413
Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)	Study Design	May/22 – Jan/26	NIH	NCT04700488
Safety Action Feedback and Engagement (SAFE) Loop	Study Design	Feb/22 – Jul/25	NIH	NCT05381441
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators	Study Design	Jan/22 – Dec/26	NIH	NCT04722341
Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System	Study Design	Sep/21 – Sep/23	Industry Funds	NCT04743310
Inhibitory Control and Pediatric Weight Management	Study Design	Aug/21 – Aug/22	Institutional Funds	NCT04747548
The Benefits of Nature-based Walking for Breast Cancer Survivors: A Pilot Study	Study Design	Jun/21 – Jul/23	Institutional Funds	NCT04896580
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy	Study Design	Apr/21 – Apr/24	Industry Funds	NCT04461509
Inhibitory Control Adult Weight Management	Study Design and Data Analysis	Feb/21 – Mar/22	Institutional Funds	NCT04747886
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL	Study Design	Feb/20 – Feb/24	Industry Funds	NCT03751709
Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency (PANCAx-3)	Study Design	Dec/20 – Dec/25	Industry Funds	NCT04098237
Voxx Human Performance Technology Socks for Chemotherapy-Induced Peripheral Neuropathy	Study Design	Oct/20 – Dec/22	Industry Funds	NCT04403802
A Mind-Body Intervention for Chemotherapy-Induced Peripheral Neuropathy (QiGong)	Study Design	Dec/19 – Mar/20	Institutional Funds	NCT04185610
Tissue Expansion in Breast Reconstruction Without Drains	Study Design	Feb/19 – Oct/20	Industry Funds	NCT03784859
Digitally-Captured Step Counts for Evaluating Performance Status in Advanced Cancer Patients (DigiSTEPS)	Study Design	Dec/18 – Dec/22	Institutional Funds	NCT03757182
Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification (PRAECIS)	Study Design and Data Analysis	Dec/18 – Oct/22	Institutional and Industry Funds	NCT03815110
Personalized Treatments for Depressive Symptoms in Patients With Advanced Heart Failure	Study Design and Data Analysis	Nov/18 – May/22	PCORI	NCT03688100
Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (WARRIOR)	Study Design	Feb/18 – Sep/23	DoD	NCT03417388
High Resolution PET-MRI Before Prostate Cancer HIFU	Study Design and Data Analysis	Dec/17 – Jan/20	Industry Funds	NCT03263780
Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors	Study Design	May/17 – Jun/23	Institutional Funds	NCT03163368

LOL: It's All Improv After Cancer! The Impact of Improvisational Comedy on Well-Being Among Patients With Cancer	Study Design	Nov/16 – Dec/17	Institutional Funds	NCT02892006
A Trial to Strengthen Existential Resiliency Among Women With Metastatic Breast Cancer	Study Design	Oct/16 – Mar/20	Institutional Funds	NCT02707510

TRAINEES

Name	Level of Trainee	Role in Training & Inclusive Dates of Training	Training Venue	Trainees' Current Status/Employment
Michael Luu	Master's level biostatistician	Mentor Nov/2016 – April/2023	Biostatistics Core	Research Biostatistician III Cedars Sinai Medical Center
Vinicius Calsavara	Research Scientist I	Mentor Oct/2020 – April/2023	Biostatistics Core	Associate Professor Cedars Sinai Medical Center
Giana Grigsby	Undergraduate in Data Science	Mentor Jun/2022 – Sep/2022	Biostatistics Core	Master's level student in Biostatistics
Sheng Tianxiang	Master's level biostatistician	Mentor May/2023 - Present	Biostatistics Core	Research Biostatistician I Icahn School of Medicine
Seungjun Ahn	Assistant Professor	Mentor Jun/2023 - Present	Biostatistics Core	Assistant Professor Icahn School of Medicine
Mu-hsun Chen	Master's level biostatistician	Mentor Sep/2023 - Present	Biostatistics Core	Research Biostatistician II Icahn School of Medicine
Karni Bedirian	Master's level biostatistician	Mentor Out/2023 - Present	Biostatistics Core	Research Biostatistician I Icahn School of Medicine

TEACHING ACTIVITIES

Teaching Activity/Topic	Level	Role	Indicate Level and Number of Learners Taught, and Venue	Number of hours week/month /year	Evaluation Summary	Years Taught
Observational Studies	Fellows	Lecturer		1 hour	Highly rated course	2023
Bayesian and Frequentist Inference	Certificate, MSCR and PhD in Clinical Research	Lecturer	Pre-doctoral and postdoctoral trainees as well as students with a bachelors degree pursuing either a Certificate, Masters or PhD in Clinical Research (37), GSBS. Icahn School of Medicine at Mount Sinai	1 hour	Highly rated course	2023
Sex as Biological Variable	Open	Lecturer	Researchers (30) Cedars Sinai Medical Center	3 hour/year	9	2020- 2023
Study Design and Research Methods	Master's in Imaging Magnetic Resonance	Director and Instructor	Students (5) Cedars Sinai Medical Center	10 hours/year	9	2018- 2022
Biostatistics	PhD in Biomedical Sciences	Director and Instructor	Students (10) Cedars Sinai Medical Center	64 hours/year	9	2016- 2022
Linear Regression	Open	Lecturer	Researchers (30) Cedars Sinai Medical Center	1 hour/year	9.5	2016- 2022

Logistic Regression	Open	Lecturer	Researchers (30) Cedars Sinai Medical Center	1 hour/year	9.5	2016-2022
Survival Analysis	Open	Lecturer	Researchers (30) Cedars Sinai Medical Center	1 hour/year	8.5	2017-2018
Biostatistics	Undergraduate	Co-Instructor	Students (40) University of São Paulo	64 hours	NA	2015
Statistics for Health Sciences	Undergraduate	Teacher Assistant	Students (40) University of São Paulo	64 hours	NA	2013
Statistics for Experimentalists	Undergraduate	Instructor	Students (20) University of Campinas	20 hours	NA	2011
Statistics for Earth Sciences	Undergraduate	Teacher Assistant	Students (120) University of Campinas	64 hours	NA	2010
Statistics for Biologists	Undergraduate	Teacher Assistant	Students (40) University of Campinas	64 hours	NA	2008
Descriptive Statistics	Undergraduate	Teacher Assistant	Students (40) University of Campinas	64 hours	NA	2007

ADMINISTRATIVE LEADERSHIP APPOINTMENTS

INTERNAL:

April/2016 – April/2023

Director for Biostatistics Course, Graduate School of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles

May/2023 - Present

Co-Director of Biostatistics and Clinical Informatics Core, Tisch Cancer Institute, Icahn School of Medicine, US

EXTERNAL:

None.

PUBLICATIONS

Peer Reviewed Original Contributions

1. Faintuch JJ, Silva FM, Navarro-Rodriguez T, Barbuti RC, Hashimoto CL, Rossini ARAL, **Diniz MA**, Eisig JN. Endoscopic findings in uninvestigated dyspepsia. BMC Gastroenterol. England; 2014 Feb 6;14:19. PMID: PMC3938027

Contributions: Data analysis and interpretation

2. Kikuchi L, Menezes M, Chagas AL, Tani CM, Alencar RSSM, **Diniz MA**, Alves VAF, D'Albuquerque LAC, Carrilho FJ. Percutaneous radiofrequency ablation for early hepatocellular carcinoma: Risk factors for survival. World Journal of Gastroenterology. 2014;20(6):1585–1593.

Contributions: Data analysis and interpretation

3. Nacif LS, David AI, Pinheiro RS, **Diniz MA**, Andraus W, Cruz RJJ, D'Albuquerque LAC. An analysis of tacrolimus-related complications in the first 30 days after liver transplantation. Clinics (Sao Paulo). United States; 2014 Nov;69(11):745–749. PMID: PMC4255082

Contributions: Data analysis and interpretation

4. Silva MF, Carrilho FJ, Paranagua-Vezozzo DC, Campos LT, Nacif LS, **Diniz MA**, Farias AQ, Alves VAF, D'Albuquerque LAC, Ono SK. m-RECIST at 1 month and Child A are survival predictors after percutaneous ethanol injection of hepatocellular carcinoma. Ann Hepatol. Mexico; 2014 Dec;13(6):796–802. PMID: 25332266

Contributions: Data analysis and interpretation

5. Cavalcante FP, Coelho AMM, Machado MCC, Sampietre SN, Patzina RA, **Diniz MA**, Chaib E, D'Albuquerque LAC. Mechanisms of the beneficial effect of sevoflurane in liver ischemia/reperfusion injury. Acta Cir Bras. Brazil; 2015 Nov;30(11):749–755. PMID: 26647794

Contributions: Data analysis and interpretation

6. Chagas AL, Kikuchi L, Herman P, Alencar RSSM, Tani CM, **Diniz MA**, Pugliese V, Rocha M de S, D'Albuquerque LAC, Carrilho FJ, Alves VAF. Clinical and pathological evaluation of fibrolamellar hepatocellular carcinoma: a single center study of 21 cases. Clinics (Sao Paulo). United States; 2015 Mar;70(3):207–213. PMID: PMC4449480

Contributions: Data analysis and interpretation

7. de Freitas IN, de Campos FGCM, Alves VAF, Cavalcante JM, Carraro D, Coudry R de A, **Diniz MA**, Nahas SC, Ribeiro UJ. Proficiency of DNA repair genes and microsatellite instability in operated colorectal cancer patients with clinical suspicion of lynch syndrome. *J Gastrointest Oncol. China*; 2015 Dec;6(6):628–637. PMID: PMC4671846

Contributions: Data analysis and interpretation

8. Eisig JN, Navarro-Rodriguez T, Teixeira ACS, Silva FM, Mattar R, Chinzon D, Haro C, **Diniz MA**, Moraes-Filho JP, Fass R, Barbuti RC. Standard Triple Therapy versus Sequential Therapy in *Helicobacter pylori* Eradication: A Double-Blind, Randomized, and Controlled Trial. *Gastroenterol Res Pract. Egypt*; 2015;2015:818043. PMID: PMC4434224

Contributions: Data analysis and interpretation

9. Jukemura J, **Diniz MA**. Qualis Periodic Evaluation: Analysis Of Qualis Upgrade In Medicine III. *Rev Col Bras Cir. Brazil*; 2015;42:54–56. PMID: 27437971

Contributions: Manuscript revising

10. Queiroz N, Kikuchi L, Bezerra R, Alencar R, Chagas A, Tani C, Diniz M, Santos A, Moreira A, Rocha M, D'Albuquerque L, Carnevale F, Carrilho F. Use of Initial Modified RECIST Tumor Response Evaluation Criteria for Predicting Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization with Drug-Eluting Beads. *Journal Cancer Therapy*. 2015;6(13):1115–1123.

Contributions: Data analysis and interpretation

11. Asperti AM, Reis P, **Diniz MA**, Pinto MD, Silva EC da J, Silva DFD da, D'Albuquerque LAC, Andraus W. The Lowest Prevalence of Cholelithiasis in the Americas - An Autopsy- based Study. *Clinics (Sao Paulo)*. United States; 2016 Jul;71(7):365–369. PMID: PMC4946535

Contributions: Data analysis and interpretation

12. de Campos Mazo DF, Mattar R, Stefano JT, da Silva-ETTO JMK, **Diniz MA**, Duarte SMB, Rabelo F, Lima RVC, de Campos PB, Carrilho FJ, Oliveira CP. Hypolactasia is associated with insulin resistance in nonalcoholic steatohepatitis. *World J Hepatol*. United States; 2016 Aug 28;8(24):1019–1027. PMID: PMC5002498

Contributions: Data analysis and interpretation

13. de Seixas Santos NASTRI AC, de Mello Malta F, **Diniz MA**, Yoshino A, Abe-Sandes K, Dos Santos SEB, de Castro Lyra A, Carrilho FJ, Pinho JRR. Association of IFNL3 and IFNL4 polymorphisms with hepatitis C virus infection in a population from southeastern Brazil. *Arch Virol. Austria*; 2016 Jun;161(6):1477–1484. PMID: 26973228

Contributions: Data analysis and interpretation

14. Kikuchi L, Oliveira CP, Alvares-da-Silva MR, Tani CM, **Diniz MA**, Stefano JT, Chagas AL, Alencar RSM, Vezozzo DCP, Santos GR, Campos PB, Alves VA, Ratzu V, Carrilho FJ. Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System. *Am J Clin Oncol*. United States; 2016 Oct;39(5):428–432. PMID: PMC5049973

Contributions: Data analysis and interpretation

15. Moreira JP, Malta F de M, **Diniz MA**, Kikuchi L, Chagas AL, Lima L de SB, Gomes-Gouvea MS, de Castro VFD, Santana RAF, Sumita NM, Paranagua Vezozzo DC, Carrilho FJ, Pinho JRR. Interferon lambda and hepatitis C virus core protein polymorphisms associated with liver cancer. *Virology*. United States; 2016 Jun;493:136–141. PMID: 27035616

Contributions: Data analysis and interpretation

16. Ximenes RO, Farias AQ, Scalabrini Neto A, **Diniz MA**, Kubota GT, Ivo MMAA, Colacique CGPS, D'Albuquerque LAC, Daglius Dias R. Patients with cirrhosis in the ED: Early predictors of infection and mortality. *American Journal of Emergency Medicine*. Elsevier Inc.; 2016;34(1):25–29.

Contributions: Data analysis and interpretation

17. **Diniz MA**, Quanlin-Li, Tighiouart M. Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method. *J Biom Biostat*. United States; 2017;8(6):381. PMID: PMC5851015

18. Kikuchi L, Chagas A, Alencar R, Tani C, Diniz M, D'Albuquerque L, Carrilho F. Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage. *Clinics*. 2017;72(08):454–460.

Contributions: Data analysis and interpretation

19. Kim EH, Preissner M, Carnibella RP, Samarage CR, Bennett E, **Diniz MA**, Fouras A, Zosky GR, Jones HD. Novel analysis of 4DCT imaging quantifies progressive increases in anatomic dead space during mechanical ventilation in mice. *J Appl Physiol* (1985). United States; 2017 Sep 1;123(3):578–584. PMID: PMC5625073

Contributions: Data analysis and interpretation

20. Landes S, Dela Cruz S, Wei J, AlBadri A, Shufelt C, Mehta P, Thomson LE, **Diniz MA**, Zhang X, Petersen JW, Anderson RD, Pepine CJ, Berman DS, Bairey Merz CN. Cold Pressor Stress Cardiac Magnetic Resonance Myocardial Flow Reserve Is Not Useful for Detection of Coronary Endothelial

Contributions: Data analysis and interpretation

21. Osada T, Morse MA, Hobeika A, **Diniz MA**, Gwin WR, Hartman Z, Wei J, Guo H, Yang XY, Liu CX, Kaneko K, Broadwater G, Lyerly HK. Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition. *Oncoimmunology*. United States; 2017;6(6):e1315495. PMID: PMC5486174

Contributions: Data analysis and interpretation

22. Tomitao MTP, Nahas SC, Kubrusly MS, Furuya TK, **Diniz MA**, Marie SKN, Safatle-Ribeiro AV, Eluf-Neto J, Ceconello I, Ribeiro Junior U. Cyclooxygenase-2 gene polymorphisms and susceptibility to colorectal cancer in a Brazilian population. *J Gastrointest Oncol*. China; 2017 Aug;8(4):629–635. PMID: PMC5582032

Contributions: Data analysis and interpretation

23. Turri JAO, Decimoni TC, Ferreira LA, **Diniz MA**, Haddad LB de P, Campolina AG. Higher MELD score increases the overall cost on the waiting list for liver transplantation: a micro-costing analysis based study. *Arq Gastroenterol*. Brazil; 2017 Sep;54(3):238–245. PMID: 28724050

Contributions: Data analysis and interpretation

24. ***Diniz MA**, Kim S, Tighiouart M. A Bayesian Adaptive Design in Cancer Phase I Trials using Dose Combinations in the Presence of a Baseline Covariate. *J Probab Stat*. United States; 2018;2018:8654173. PMID: PMC6428433

25. *Osada T, Hartman ZC, Wei J, Lei G, Hobeika AC, Gwin WR, **Diniz MA**, Spector N, Clay TM, Chen W, Morse MA, Lyerly HK. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. *Breast Cancer Res*. England; 2018 Aug 9;20(1):90. PMID: PMC6085609

Contributions: Data analysis and interpretation

26. *Riccioppo D, Santo MA, Rocha M, Buchpiguel CA, **Diniz MA**, Pajecki D, de Cleva R, Kawamoto F. Small-Volume, Fast-Emptying Gastric Pouch Leads to Better Long-Term Weight Loss and Food Tolerance After Roux-en-Y Gastric Bypass. *Obes Surg*. United States; 2018 Mar;28(3):693–701. PMID: 28913642

Contributions: Data analysis and interpretation

27. *Rosen BT, Halbert RJ, Hart K, **Diniz MA**, Isonaka S, Black JT. The Enhanced Care Program: Impact of a Care Transition Program on 30-Day Hospital Readmissions for Patients Discharged From an Acute Care Facility to Skilled Nursing Facilities. *J Hosp Med*. United States; 2018 Apr 1;13(4):229–236. PMID: 29069115

Contributions: Data analysis and interpretation

28. *Sharma S, Mehta PK, Arsanjani R, Sedlak T, Hobel Z, Shufelt C, Jones E, Kligfield P, Mortara D, Laks M, **Diniz MA**, Bairey Merz CN. False-positive stress testing: Does endothelial vascular dysfunction contribute to ST-segment depression in women? A pilot study. *Clin Cardiol*. United States; 2018 Aug;41(8):1044–1048. PMID: PMC6153069

Contributions: Data analysis and interpretation

29. *Silvestre OM, Farias AQ, Ramos DS, Furtado MS, Rodrigues AC, Ximenes RO, de Campos Mazo DF, Yoshimura Zitelli PM, **Diniz MA**, Andrade JL, Strunz C, Friedmann AA, Lee SS, Carrilho FJ, D'Albuquerque LAC, Bacal F. beta-Blocker therapy for cirrhotic cardiomyopathy: a randomized-controlled trial. *Eur J Gastroenterol Hepatol*. England; 2018 Aug;30(8):930–937. PMID: 29979644

Contributions: Data analysis and interpretation

30. *Wu F, Ma Q, Song H, Guo X, **Diniz MA**, Song SS, Gonzalez NR, Bi X, Ji X, Li D, Yang Q, Fan Z. Differential Features of Culprit Intracranial Atherosclerotic Lesions: A Whole-Brain Vessel Wall Imaging Study in Patients With Acute Ischemic Stroke. *J Am Heart Assoc*. England; 2018 Jul 22;7(15):e009705. PMID: PMC6201468

Contributions: Data analysis and interpretation

31. *Zhang N, Zhang F, Deng Z, Yang Q, **Diniz MA**, Song SS, Schlick KH, Marcel Maya M, Gonzalez N, Li D, Zheng H, Liu X, Fan Z. 3D whole-brain vessel wall cardiovascular magnetic resonance imaging: a study on the reliability in the quantification of intracranial vessel dimensions. *J Cardiovasc Magn Reson*. England; 2018 Jun 14;20(1):39. PMID: PMC6000985

Contributions: Data analysis and interpretation

32. *Chagas AL, Felga GEG, **Diniz MA**, Silva RF, Mattos AA, Silva RCMA, Boin IFSF, Garcia JHP, Lima AS, Coelho JCU, Bittencourt PL, Alves VAF, D'Albuquerque LAC, Carrilho FJ. Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival. *Eur J Gastroenterol Hepatol*. England; 2019 Sep;31(9):1148–1156. PMID: PMC6687037

Contributions: Data analysis and interpretation

33. ***Diniz MA**, Tighiouart M, Rogatko A. Comparison between continuous and discrete doses for model based designs in cancer dose finding. *PLoS One*. United States; 2019;14(1):e0210139. PMID: PMC6326565
34. *Raquel Benedita Terrabuio D, Augusto **Diniz MA**, Teofilo de Moraes Falcao L, Luiza Vilar Guedes A, Akeme Nakano L, Silva Evangelista A, Roberto Lima F, Pires Abrantes-Lemos C, Jose Carrilho F, Luiz Rachid Cancado E. Chloroquine Is Effective for Maintenance of Remission in Autoimmune Hepatitis: Controlled, Double-Blind, Randomized Trial. *Hepatol Commun*. United States; 2019 Jan;3(1):116–128. PMID: PMC6312658
- Contributions: Study design, data analysis and interpretation
35. ***Diniz MA**, Kim S, Tighiouart M. A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades. *Stats (Basel)*. Switzerland; 2020 Sep;3(3):221–238. PMID: PMC7561046
36. Gresham G, **Diniz MA**, Razaee ZS, Luu M, Kim S, Hays RD, Piantadosi S, Tighiouart M, Yothers G, Ganz PA, Rogatko A. Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index. *J Natl Cancer Inst*. United States; 2020 Dec 14;112(12):1266–1274. PMID: PMC7735773
- Contributions: Data analysis and interpretation, manuscript draft and revising
37. *Ishak WW, Edwards G, Herrera N, Lin T, Hren K, Peterson M, Ngor A, Liu A, Kimchi A, Spiegel B, Hedrick R, Chernoff R, **Diniz MA**, Mirocha J, Manoukian V, Ong M, Harold J, Danovitch I, Hamilton M. Depression in Heart Failure: A Systematic Review. *Innov Clin Neurosci*. United States; 2020 Apr 1;17(4–6):27–38. PMID: PMC7413333
- Contributions Manuscript revising
38. *Kaneko K, Osada T, Morse MA, Gwin WR, Ginzel JD, Snyder JC, Yang XY, Liu CX, **Diniz MA**, Bodoor K, Hughes PF, Haystead TA, Lyerly HK. Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors. *Commun Biol*. England; 2020 May 8;3(1):226. PMID: PMC7210113
- Contributions: Data analysis and interpretation
39. *Marchevsky AM, **Diniz MA**, Manzoor D, Walts AE. Prognosis in pathology: Are we “prognosticating” or only establishing correlations between independent variables and survival? A study with various analytics cautions about the overinterpretation of statistical results. *Ann Diagn Pathol*. United States; 2020 Jun;46:151525. PMID: 32353712
- Contributions: Manuscript drafting and revising
40. *Nunes VS, Andrade AR, Guedes ALV, **Diniz MA**, Oliveira CP, Cancado ELR. Distinct Phenotype Of Non-Alcoholic Fatty Liver Disease In Patients With Low Levels Of Free Copper And Of Ceruloplasmin. *Arq Gastroenterol*. Brazil; 2020 Sep;57(3):249–253. PMID: 32935743
- Contributions: Data analysis and interpretation
41. *Pinheiro RS, Andraus W, Waisberg DR, Nacif LS, Ducatti L, Rocha-Santos V, **Diniz MA**, Arantes RM, Lerut J, D’Albuquerque LAC. Abdominal hernias in cirrhotic patients: Surgery or conservative treatment? Results of a prospective cohort study in a high volume center: Cohort study. *Ann Med Surg (Lond)*. England; 2020 Jan;49:9–13. PMID: PMC6911966
- Contributions: Data analysis and interpretation
42. *Silva MADS, **Diniz MA**, Carvalho RT de, Chiba T, Mattos-Pimenta CA de. Palliative care consultation team: symptom relief in first 48 hours of hospitalization. *Rev Bras Enferm*. Brazil; 2020;73(6):e20190391. PMID: 32785516
- Contributions: Data analysis and interpretation
43. *T de Moraes Falcao L, Terrabuio DRB, **Diniz MA**, da Silva Evangelista A, Souza FG, R Cancado EL. Efficacy and safety of chloroquine plus prednisone for the treatment of autoimmune hepatitis in a randomized trial. *JGH Open*. Australia; 2020 Jun;4(3):371–377. PMID: PMC7273702
- Contributions: Data analysis and interpretation
44. *Asher A, Kim S, **Diniz MA**, Mack A, Shirazipour CH. The Impact of Improvisational Theater/Comedy on Well-Being Among Breast Cancer Survivors: A Pilot Feasibility Study. *Alternative and Complementary Therapies*. Mary Ann Liebert, Inc., publishers; 2021 Dec 1;27(6):276–284.
- Contributions: Supervision of data analysis and interpretation
45. *Azadani PN, Miller RJH, Sharir T, **Diniz MA**, Hu LH, Otaki Y, Gransar H, Liang JX, Eisenberg E, Einstein AJ, Fish MB, Ruddy TD, Kaufmann PA, Sinusas AJ, Miller EJ, Bateman TM, Dorbala S, Di Carli M, Tamarappoo BK, Dey D, Berman DS, Slomka PJ. Impact of Early Revascularization on Major Adverse Cardiovascular Events in Relation to Automatically Quantified Ischemia. *JACC Cardiovasc Imaging*. United States; 2021 Mar;14(3):644–653. PMID: PMC7987223
- Contributions: Data analysis and interpretation
46. *Berdahl CT, Nguyen AT, **Diniz MA**, Henreid AJ, Nuckols TK, Libby CP, Pevnick JM. Using body temperature and variables commonly available in the EHR to predict acute infection: a proof-of-concept study showing improved pretest probability estimates for acute COVID-19 infection among discharged emergency department patients. *Diagnosis (Berl)*. Germany; 2021 Nov 25;8(4):450–457. PMID: 34187134

Contributions: Supervision of data analysis and interpretation

47. *Chagas AL, Mattos AA, **Diniz MA**, Felga GEG, Boin IFSF, Silva RCMA, Silva RF, Garcia JHP, Lima AS, Coelho JCU, Bittencourt PL, Alves VAF, D'Albuquerque LAC, Carrilho FJ. Impact of Brazilian expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a multicenter study. *Ann Hepatol. Mexico*; 2021 Jun;22:100294. PMID: 33276136

Contributions: Data analysis and interpretation

48. *Crescente JG, Dellavance A, **Diniz MA**, Carrilho FJ, Andrade LEC de, Cancado ELR. Antineutrophil cytoplasmic antibody profiles differ according to type of primary sclerosing cholangitis and autoimmune hepatitis. *Clinics (Sao Paulo). United States*; 2021;76:e2228. PMCID: PMC7847259

Contributions: Data analysis and interpretation, manuscript drafting and revising

49. ***Diniz MA**, Gresham G, Kim S, Luu M, Henry NL, Tighiouart M, Yothers G, Ganz PA, Rogatko A. Visualizing adverse events in clinical trials using correspondence analysis with R-package visae. *BMC Med Res Methodol. England*; 2021 Nov 9;21(1):244. PMCID: PMC8579548

50. *Henry NL, Kim S, Hays RD, **Diniz MA**, Luu M, Cecchini RS, Yothers G, Rogatko A, Ganz PA. Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35. *J Clin Oncol. United States*; 2021 Dec 1;39(34):3800–3812. PMCID: PMC8629339

Contributions: Data analysis and interpretation, manuscript drafting and revising

51. *IsHak WW, Korouri S, Darwish T, Vanle B, Dang J, Edwards G, Black JT, Aronow H, Kimchi A, Spiegel B, Hedrick R, Chernoff R, **Diniz MA**, Mirocha J, Manoukian V, Harold J, Ong MK, Wells K, Hamilton M, Danovitch I. Personalized treatments for depressive symptoms in patients with advanced heart failure: A pragmatic randomized controlled trial. *PLoS One. United States*; 2021;16(1):e0244453. PMCID: PMC7790529

Contributions: Study design

52. *Kaisey M, Solomon AJ, Guerrero BL, Renner B, Fan Z, Ayala N, Luu M, **Diniz MA**, Sati P, Sicotte NL. Preventing multiple sclerosis misdiagnosis using the “central vein sign”: A real-world study. *Mult Scler Relat Disord. Netherlands*; 2021 Feb;48:102671. PMID: 33444958

Contributions: Supervision of data analysis and interpretation

53. *Kuronuma K, Miller RJH, Otaki Y, Van Krieking SD, **Diniz MA**, Sharir T, Hu LH, Gransar H, Liang JX, Parekh T, Kavanagh PB, Einstein AJ, Fish MB, Ruddy TD, Kaufmann PA, Sinusas AJ, Miller EJ, Bateman TM, Dorbala S, Di Carli M, Tamarappoo BK, Dey D, Berman DS, Slomka PJ. Prognostic Value of Phase Analysis for Predicting Adverse Cardiac Events Beyond Conventional Single-Photon Emission Computed Tomography Variables: Results From the REFINE SPECT Registry. *Circ Cardiovasc Imaging. United States*; 2021 Jul;14(7):e012386. PMCID: PMC8978932

Contributions: Supervision of data analysis and interpretation

54. *Razae ZS, Amini AA, **Diniz MA**, Tighiouart M, Yothers G, Rogatko A. On the properties of the toxicity index and its statistical efficiency. *Stat Med. England*; 2021 Mar 15;40(6):1535–1552. PMCID: PMC7953898

Contributions: Manuscript drafting and revising

55. *Rogatko CP, Weisse C, Schwarz T, Berent AC, **Diniz MA**. Drug-eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial. *J Vet Intern Med. United States*; 2021 May;35(3):1487–1495. PMCID: PMC8162590

Contributions: Data analysis and interpretation

56. *Xiao J, Padrick MM, Jiang T, Xia S, Wu F, Guo Y, Gonzalez NR, Li S, Schlick KH, Dumitrascu OM, Maya MM, **Diniz MA**, Song SS, Lyden PD, Li D, Yang Q, Fan Z. Acute ischemic stroke versus transient ischemic attack: Differential plaque morphological features in symptomatic intracranial atherosclerotic lesions. *Atherosclerosis. Ireland*; 2021 Feb;319:72–78. PMCID: PMC7880900

Contributions: Data analysis and interpretation

57. *Caceres NA, Yu Q, Capaldi J, **Diniz MA**, Raynor H, Foster GD, Seitz AR, Salvy SJ. Evaluating environmental and inhibitory control strategies to improve outcomes in a widely available weight loss program. *Contemp Clin Trials. United States*; 2022 Aug;119:106844. PMCID: PMC9420799

Contributions: Study design

58. *Caceres NA, Yu Q, Lauzon M, **Diniz MA**, Tuckerman R, Carrillo A, Philipp M, Foster GD, Seitz AR, Salvy SJ. Supplementing a widely available weight loss program with gamified inhibitory control training: A randomized pilot study. *Obes Sci Pract. United States*; 2022 Dec;8(6):775–783. PMCID: PMC9722449

Contributions: Study design, Supervision of data analysis and interpretation

59. *Iribarren A, **Diniz MA**, Merz CNB, Shufelt C, Wei J. Are we any WISER yet? Progress and contemporary need for smart trials to include women in coronary artery disease trials. *Contemp Clin Trials. United States*; 2022 Jun;117:106762. PMCID: PMC9156573

Contributions: Manuscript drafting and revising

60. *Leggett CB, Naqvi M, Esakoff TF, **Diniz MA**, Wong MS. Incorporating personal-device-based point-of-care ultrasound into obstetric care: a validation study. *Am J Obstet Gynecol*. United States; 2022 Apr;226(4):552.e1-552.e6. PMID: 34774825

Contributions: Study design, data analysis and interpretation

61. *Lyden PD, Bosetti F, **Diniz MA**, Rogatko A, Koenig JI, Lamb J, Nagarkatti KA, Cabeen RP, Hess DC, Kamat PK, Khan MB, Wood K, Dhandapani K, Arbab AS, Leira EC, Chauhan AK, Dhanesha N, Patel RB, Kumskova M, Thedens D, Morais A, Imai T, Qin T, Ayata C, Boisserand LSB, Herman AL, Beatty HE, Velazquez SE, Diaz-Perez S, Sanganahalli BG, Mihailovic JM, Hyder F, Sansing LH, Koehler RC, Lannon S, Shi Y, Karuppagounder SS, Bibic A, Akhter K, Aronowski J, McCullough LD, Chauhan A, Goh A. The Stroke Preclinical Assessment Network: Rationale, Design, Feasibility, and Stage 1 Results. *Stroke*. United States; 2022 May;53(5):1802–1812. PMID: PMC9038686

Contributions: Study design, data analysis and interpretation, manuscript drafting

62. *Mastali M, Asif A, Fu Q, Wei J, Korley FK, Peacock WF, Sobhani K, Cook-Wiens G, **Diniz MA**, Merz CNB, Van Eyk JE. Ultra-highly sensitive cardiac troponin I: Age and sex differences in healthy individuals. *American Heart Journal Plus: Cardiology Research and Practice*. 2022 Jan 1;13:100110.

Contributions: Data analysis and interpretation

63. *Rios R, Miller RJH, Hu LH, Otaki Y, Singh A, **Diniz MA**, Sharir T, Einstein AJ, Fish MB, Ruddy TD, Kaufmann PA, Sinusas AJ, Miller EJ, Bateman TM, Dorbala S, DiCarli M, Van Kriekinge S, Kavanagh P, Parekh T, Liang JX, Dey D, Berman DS, Slomka P. Determining a minimum set of variables for machine learning cardiovascular event prediction: results from REFINE SPECT registry. *Cardiovasc Res*. England; 2022 Jul 20;118(9):2152–2164. PMID: PMC9302886

Contributions: Supervision of data analysis and interpretation

64. *Tighiouart M, Jiménez JL, **Diniz MA**, Rogatko A. Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value? *Brazilian Journal of Biometrics*. 2022 31;40(4):453–468.

Contributions: Manuscript revising

65. *Waldron RT, Jones EK, Anani VI, Hines JM, Zhao J, Lugea A, **Diniz MA**, Kim S, Habtezion A, Hoffman KL, Petrosino JF, Fisher WE, Li L, Lennon RJ, Singh RJ, Vege SS, Pandol SJ, Topazian MD. Salivary Biomarker Evaluation of Chronic Pancreatitis Patients Reveals Alterations in Human Proteins, Cytokines, Prostaglandin E2 Levels, and Bacterial Diversity. *Pancreas*. United States; 2022 Aug 1;51(7):723–732. PMID: PMC9681020

Contributions: Data analysis

66. *Wu J, Raz Y, Recouvreur MS, **Diniz MA**, Lester J, Karlan BY, Walts AE, Gertych A, Orsulic S. Focal Serous Tubal Intra-Epithelial Carcinoma Lesions Are Associated With Global Changes in the Fallopian Tube Epithelia and Stroma. *Front Oncol*. Switzerland; 2022;12:853755. PMID: PMC8977528

Contributions: Supervision of data analysis and interpretation

67. *Xiao J, Song SS, Schlick KH, Xia S, Jiang T, Han T, Jackson RJ, **Diniz MA**, Dumitrascu OM, Maya MM, Lyden PD, Li D, Yang Q, Fan Z. Disparate trends of atherosclerotic plaque evolution in stroke patients under 18-month follow-up: a 3D whole-brain magnetic resonance vessel wall imaging study. *Neuroradiol J*. United States; 2022 Feb;35(1):42–52. PMID: PMC8826292

Contributions: Data analysis and interpretation

68. *Rogatko C, Weisse C, Schwarz T, Berent A, **Diniz MA**. Comparison of computed tomography response criteria after chemoembolization of hepatic carcinoma in dogs. *Can J Vet Res*. Canada; 2023 Jan;87(1):74–81. PMID: PMC9808882

Contributions: Data analysis and interpretation

69. *Calsavara VF, **Diniz MA**, Tighiouart M, Ganz PA, Henry NL, Hays RD, Yothers G, Rogatko A. Simulation study comparing analytical methods for single-item longitudinal patient-reported outcomes data. *Quality of Life Research*. 2023 Mar;32(3):827-39. PMID: PMC9992042

Contributions: Data acquisition, data analysis and manuscript drafting

70. *Shirazipour CH, Raines C, **Diniz MA**, Salvy SJ, Haile RW, Freedland SJ, Asher A, Tomasone JR, Gresham G. The 24-Hour Movement Paradigm: An integrated approach to the measurement and promotion of daily activity in cancer clinical trials. *Contemporary Clinical Trials Communications*. 2023 Apr 1;32:101081. PMID: PMC9974421

Contributions: Drafting manuscript

71. *Fenske SJ, Liu J, Chen H, **Diniz MA**, Stephens RL, Cornea E, Gilmore JH, Gao W. Sex differences in resting state functional connectivity across the first two years of life. *Developmental Cognitive Neuroscience*. 2023 Apr 1;60:101235. PMID: PMC10066534

Contributions: Supervision of data analysis and interpretation

72. *Asher A, Shirazipour CH, Capaldi JM, Kim S, **Diniz MA**, Jones B, Wertheimer J. A 6-Week Program to Strengthen Resiliency Among Women With Metastatic Cancer: A Randomized Clinical Trial. *The Oncologist*. 2023 Apr 27:oyad091. PMID: 37104871

Contributions: Study design, supervision of data analysis and interpretation

73. ***Diniz MA**, Gallardo DI, Magalhães TM. Improved inference for MCP-Mod approach using time-to-event endpoints with small sample sizes. *Pharmaceutical Statistics*. 2023 Apr 29. PMID: 37119000
74. *Shirazipour CH, Raines C, Liu E, Ruggieri RM, Capaldi JM, Luna-Lupercio B, **Diniz MA**, Gresham G, Bhowmick N, Haile RW, Asher A. Benefits of nature-based walking for breast cancer survivors. *BMJ open*. 2023 Jun 1;13(6):e071041. PMID: PMC10277127

Contributions: Study design

75. *Hitchins MP, Dámaso E, Alvarez R, Zhou L, Hu Y, **Diniz MA**, Pineda M, Capella G, Pearlman R, Hampel H. Constitutional MLH1 Methylation Is a Major Contributor to Mismatch Repair-Deficient, MLH1-Methylated Colorectal Cancer in Patients Aged 55 Years and Younger. *Journal of the National Comprehensive Cancer Network*. 2023 Jul 1;21(7):743-52. PMID: 37433431

Contributions: Data analysis and interpretation

76. Pevnick JM, Diniz MA, Magoffin D, Ishimori M, Bairey Merz CN. Microvascular aging and eicosanoids-women's evaluation of systemic aging tenacity ("you are never too old to become younger!") specialized center of research excellence on sex differences career enhancement core: Building the future. *Journal of Women's Health*. 2023 Aug 1;32(8):883-90. PMID: PMC10623456

Contributions: Data analysis and interpretation

77. Lyden PD, **Diniz MA**, Bosetti F, Lamb J, Nagarkatti KA, Rogatko A, Kim S, Cabeen RP, Koenig JI, Akhter K, Arbab AS. A multi-laboratory preclinical trial in rodents to assess treatment candidates for acute ischemic stroke. *Science translational medicine*. 2023 Sep 20;15(714):eadg8656. PMID: 37729432

Contributions: Study design, data analysis and interpretation

78. Pearson B, Pulley M, **Diniz MA**, Baca N, Majlessipour F. Loss of humeral immunity in childhood cancer survivors not having undergone hematopoietic stem cell transplantation. *Cancer Reports*. 2023 Oct 22:e1907. PMID: 37867406

Contributions: Supervision of data analysis and interpretation

79. Calsavara VF, Henry NL, Hays RD, Kim S, Luu M, **Diniz MA**, Gresham G, Cecchini RS, Yothers G, Ganz PA, Rogatko A. Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial. *Cancer Prevention Research*. 2023 Nov 1;16(11):631-9. PMID: PMC10618646

Contributions: Manuscript drafting

- Invited Contributions

1. **Diniz MA**. Statistical methods for validation of predictive models. *J Nucl Cardiol*. United States; 2022 Dec;29(6):3248–3255. PMID: 35610537

- Books and Book Chapters

1. **Diniz MA**, de Bragança Pereira CA, Polpo A. Bayesian semiparametric symmetric models for binary data. *Interdisciplinary Bayesian Statistics*. Springer International Publishing, 2015. 323-335.
2. Magalhães TM, **Diniz MA**. Normality: Assumptions, Transformations and Outliers. In: Lunardi C Adriana (eds) *Manual of Clinical Research Applied to Health*. Blucher, 2020. 349-364
3. **Diniz MA**, Magalhães TM. Logistic Regression and Related Methods. In: Piantadosi S., Meinert C. (eds) *Principles and Practice of Clinical Trials*. Springer International Publishing, 2020.
4. Jiménez JL, **Diniz MA**, Rogatko A, Tighiouart M. Designs of Early Phase Cancer Trials with Drug Combinations. In: *Modern Statistical Methods for Health Research*. Springer, Cham. 2021. 131-160.

- Computer Software
1. **Diniz, MA.** EWOC: Escalation With Overdose Control.
<https://cran.r-project.org/web/packages/ewoc/index.html>
Role: Author, Maintainer
 2. **Diniz, MA.** ntimes: Wrappers for basic statistical analysis.
<https://github.com/dnzmarcio/ntimes>
Role: Author, Maintainer
 3. **Diniz, MA.** visae: Visualization of Adverse Events.
<https://cran.r-project.org/web/packages/visae/index.html>
Role: Author, Maintainer
 4. **Diniz MA.** MCPModBC: Improved Inference in Multiple Comparison Procedure – Modelling
<https://cran.r-project.org/web/packages/MCPModBC/>
Role: Author
 5. **Diniz, MA.** marginaleffects: Predictions, Comparisons, Slopes, Marginal Means, and Hypothesis Tests
<https://cran.r-project.org/web/packages/marginaleffects/index.html>
Role: Contributor

INVITED PRESENTATIONS

1. Short-term biomarkers as endpoints in Bayesian seamless phase II-III clinical trials, Federal University of São Carlos, São Carlos, Brazil, 2020
2. Statistical methods to redefine Liver Transplantation Criteria in Brazil, Federal University of Juiz de Fora, Juiz de Fora, Brazil, 2021
3. Statistical methods to redefine Liver Transplantation Criteria in Brazil, Federal University of Viçosa, Florestal, Brazil, 2021
4. Shrinkage priors for single cell experiments, IX Workshop on Probabilistic and Statistical Methods, Federal University of São Carlos, São Carlos, Brazil, 2022
5. Short-term biomarkers as endpoints in Bayesian seamless phase II-III clinical trials, Icahn School of Medicine at Mount Sinai, New York, US, 2022
6. Opportunities of collaboration between biostatisticians and pre-clinical scientists: a literature review, Icahn School of Medicine, New York, US, 2023

MEDIA RESOURCE EDUCATIONAL MATERIALS

1. **Diniz, MA.** Statistical Analysis and Probability: The fortune teller – Teacher Guide (In Portuguese). Multimedia Mathematics – E-learning: <https://m3.ime.unicamp.br/recursos/1065>
2. **Diniz, MA.** Statistical Analysis and Probability: Scientific Kitchen – Teacher Guide (In Portuguese). Multimedia Mathematics – E-learning: <https://m3.ime.unicamp.br/recursos/1077>
3. **Diniz, MA.** Statistical Analysis and Probability: Dance Night – Teacher Guide (In Portuguese). Multimedia Mathematics – E-learning: <https://m3.ime.unicamp.br/recursos/1139>
4. **Diniz, MA.** Statistical Analysis and Probability: Pregnancy test – Teacher Guide (In Portuguese). Multimedia Mathematics – E-learning: <https://m3.ime.unicamp.br/recursos/1184>
5. **Diniz, MA.** Numbers and Functions: The brief story of the end – Teacher Guide (In Portuguese). Multimedia Mathematics – E-learning: <https://m3.ime.unicamp.br/recursos/1057>
6. **Diniz, MA.** Numbers and Functions: The difference between cousins – Teacher Guide (In Portuguese). Multimedia Mathematics – E-learning: <https://m3.ime.unicamp.br/recursos/1310>
7. **Diniz, MA.** Numbers and Functions: Subsets – Teacher Guide (In Portuguese). Multimedia Mathematics – E-learning: <https://m3.ime.unicamp.br/recursos/1320>
8. **Diniz MA.** Geometry: It all starts with pizza – Teacher Guide (In Portuguese). Multimedia Mathematics – E-learning: <https://m3.ime.unicamp.br/recursos/1325>
9. **Diniz, MA,** Pevnick J. and Bairey-Merz N. Studying Sex to Strengthen Science: Sex as Biological Variable. NIH Career Development and Education – E-learning: <https://orwh.od.nih.gov/career-development-education/e-learning/sabv-primer-supplement>
10. **Diniz MA,** Luu M. Introduction to Biostatistics using R for Biosciences. Course Material: https://dnzmarcio.github.io/cshs_bms510_biostatistics_course/

VOLUNTARY PRESENTATIONS – e.g. abstracts, poster presentations

1. **Diniz MA**, Hotta, LK. Stochastic and Deterministic models: modelling epidemics. XVI Congress of Undergraduate Research, Campinas, Brazil, 2008.
2. **Diniz MA**, Achcar, JA, Hotta, LK. Stochastic and Deterministic models: modelling epidemics. XIX National Symposium of Probability and Statistic, Águas de São Pedro, Brazil, 2010.
3. **Diniz MA**, Achcar, JA, Hotta, LK. Bayesian analysis for SEIR models with missing data. V Scientific Meeting of Graduate Students in Statistics, Campinas, Brazil, 2010.
4. **Diniz MA**, Achcar, JA, Hotta, LK. Bayesian analysis for SEIR models with missing data. II Bayesian Statistical Meeting, São Paulo, Brazil, 2010.
5. **Diniz MA**, Tavares LC, Calsavara V. Median Loss decision criteria. XI Brazilian Meeting of Bayesian Statistic, Amparo, Brazil, 2012.
6. **Diniz MA**, Achcar, JA, Hotta, LK. SEIR models with non-homogeneous remove rate. XX National Symposium of Probability and Statistic, João Pessoa, Brazil, 2012.
7. **Diniz MA**, de Bragança Pereira CA, Polpo A. Bayesian semi-parametric symmetric models for binary data. XII Brazilian Meeting of Bayesian Statistic, Atibaia, Brazil, 2014.
8. **Diniz MA**, de Bragança Pereira CA, Polpo A. Bayesian semi-parametric symmetric models for binary data. XXI National Symposium of Probability and Statistic, Natal, Brazil, 2014.
9. **Diniz MA**, de Bragança Pereira CA, Polpo A. Bayesian semi-parametric models for binary data. XIV School of Regression Models, Campinas, Brazil, 2015.
10. **Diniz MA**, Tighiouart M, Rogatko A. Comparison between Discrete and Continuous Doses for Escalation With Overdose Designs, Joint Statistical Meeting, Chicago, US, 2016.
11. **Diniz MA**, Tighiouart M, Rogatko A. Design of Drug Combination Early Phase Cancer Trials Using Time to Toxicity Data, Joint Statistical Meeting, Baltimore, US, 2017.
12. **Diniz MA**, Couch MO, Razaee ZS, and Rogatko A. Bayesian Agnostic Multiple Hypotheses Test with Decision-Errors Control, Joint Statistical Meeting, Denver, US, 2018.

Updated August 2023